Abstract
The deposition of cholesterol in the arterial wall by the infiltration of low-density lipoproteins (LDLs) is a key step in the development of atherosclerosis. In this Commentary, we discuss recent recommendations for clinical laboratory measurement of low-density lipoprotein cholesterol (LDL-C) and its utility both for assessing cardiovascular disease risk and as a tool in the management of patients receiving lipid-lowering therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 20-22 |
| Number of pages | 3 |
| Journal | Clinical Pharmacology and Therapeutics |
| Volume | 96 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2014 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Measurement of low-density lipoprotein cholesterol in assessment and management of cardiovascular disease risk. / Jialal, I.; Remaley, A. T.
In: Clinical Pharmacology and Therapeutics, Vol. 96, No. 1, 2014, p. 20-22.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Measurement of low-density lipoprotein cholesterol in assessment and management of cardiovascular disease risk
AU - Jialal, I.
AU - Remaley, A. T.
PY - 2014
Y1 - 2014
N2 - The deposition of cholesterol in the arterial wall by the infiltration of low-density lipoproteins (LDLs) is a key step in the development of atherosclerosis. In this Commentary, we discuss recent recommendations for clinical laboratory measurement of low-density lipoprotein cholesterol (LDL-C) and its utility both for assessing cardiovascular disease risk and as a tool in the management of patients receiving lipid-lowering therapy.
AB - The deposition of cholesterol in the arterial wall by the infiltration of low-density lipoproteins (LDLs) is a key step in the development of atherosclerosis. In this Commentary, we discuss recent recommendations for clinical laboratory measurement of low-density lipoprotein cholesterol (LDL-C) and its utility both for assessing cardiovascular disease risk and as a tool in the management of patients receiving lipid-lowering therapy.
UR - http://www.scopus.com/inward/record.url?scp=84902667376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902667376&partnerID=8YFLogxK
U2 - 10.1038/clpt.2014.69
DO - 10.1038/clpt.2014.69
M3 - Article
C2 - 24942398
AN - SCOPUS:84902667376
VL - 96
SP - 20
EP - 22
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
SN - 0009-9236
IS - 1
ER -